2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
25
Neoplasms
12
Giant Cell Tumor of Bone
10
Prostatic Neoplasms
9
Multiple Myeloma
9
Neoplasm Metastasis
8
Osteoporosis
4
Fractures, Bone
4
Carcinoma, Non-Small-Cell Lung
4
Recurrence
3
Kidney Neoplasms
3
Carcinoma, Renal Cell
3
Bone Neoplasms
3
Bone Diseases, Metabolic
3
Bone Diseases
3
Spinal Cord Compression
2
Smoldering Multiple Myeloma
2
Parathyroid Neoplasms
2
Melanoma
2
Lymphoma
2
Lung Neoplasms
2
Giant Cell Tumors
2
Bone Metastases
2
Bone Cysts, Aneurysmal
2
With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer Metastatic
1
Paraproteinemias
1
Interventions
Paclitaxel
11
Carboplatin
8
Radiotherapy
7
Letrozole
7
Cyclophosphamide
7
Trastuzumab
5
Chemotherapy, Adjuvant
5
Doxorubicin
4
Brachytherapy
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
atamestane
3
Toremifene
3
Tamoxifen
3
Radiotherapy, Conformal
3
Magnetic Resonance Spectroscopy
3
Epirubicin
3
Docetaxel
3
Cryosurgery
3
Cisplatin
3
pertuzumab
2
Surgical Procedures, Operative
2
Radiation
2
Lapatinib
2
Fulvestrant
2
Estrogen Receptor Modulators
2
Cryotherapy
2
Capecitabine
2
Biopsy
2
Aromatase Inhibitors
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Ductal, Breast
×
Denosumab
×
Clear all
NCT02682693
2021-02-02
GeparX
GBG Forschungs GmbH
Phase 2
Completed
780 enrolled